Previous 10 | Next 10 |
Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that preclinical data for BT7480, a tumor-targeted immune cell agoni...
Bicycle Therapeutics (BCYC): Q3 GAAP EPS of -$0.52 beats by $0.12.Revenue of $3.84M (+529.5% Y/Y) beats by $1.24M.Press Release For further details see: Bicycle Therapeutics EPS beats by $0.12, beats on revenue
- Three clinical trials of novel Bicycles ® initiated this quarter, including a Phase IIa for BT1718, a Phase I for BT8009, and a Phase II for THR-149 - Cash was $149.8 million at September 30, 2020, which includes net proceeds received during Q3 from completion o...
- Four renowned experts join to advise Bicycle as the company advances pipeline of novel cancer therapeutic candidates Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicy...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that preclinical data for BT7480, a tumor-targeted immune cell ...
Bicycle Therapeutics (BCYC) completed its at-the-market offering program initiated during Q3 generating gross proceeds of $50M.Also, it closed a financing with Hercules Capital (HTGC) for a term loan of up to $40M in two tranches; an initial tranche of $30M will be fully available a...
- ATM offering program initiated during Q3’20 fully utilized; $15.0 million drawn on debt financing facility of up to $40.0 million - Approximately $70 million generated during Q3’20 including ATM proceeds, debt financing draw and previously announced $6.7 millio...
VBL Therapeutics reports progress for metastatic colorectal cancer trial VBL Therapeutics ( VBLT ) announced the enrollment of the first two patients for its Phase 2 clinical trial of VB-111. The trial is designed to evaluate the potential of VB-111 used in combination with nivolumab for...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that a poster describing the design of the ongoing Phase I/II trial of BT8009 wi...
The first patient has been dosed in an open-label Phase 1/2 clinical trial evaluating Bicycle Therapeutics' (NASDAQ: BCYC ) BT8009, a Bicycle Toxin Conjugate (BTC) targeting a tumor antigen called nectin-4, in patients with advanced solid tumors. More news on: Bicycle Therapeutics plc,...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced the acceptance of four abstracts for poster presentation at the European So...
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...